Opinion
Video
Complement Inhibitors for Treatment of Generalized Myasthenia Gravis
Author(s):
Key Takeaways
- Complement inhibitors target the C5 component of the complement cascade, preventing membrane attack complex formation and reducing neuromuscular junction damage.
- Clinical trials show significant efficacy in improving muscle strength and reducing symptoms in gMG patients.
Panelists discuss how complement inhibitors work to treat generalized myasthenia gravis (gMG), evaluating their efficacy and safety profiles based on FDA approvals and clinical experience.
Video content above is prompted by the following:
- Complement inhibitor agents have been approved by the FDA for treatment of gMG. Provide an overview of their mechanism of action and your overall impressions of the efficacy and safety of these agents.
Related Videos
Related Content
